

PERSPECTIVE

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Christopher J. Weber¹ | Maria C. Carrillo¹ | William Jagust² | Clifford R. Jack Jr³ | Leslie M. Shaw⁴ | John Q. Trojanowski⁵ | Andrew J. Saykin⁶ | Laurel A. Beckett⁷ | Cyrille Sur⁸ | Naren P. Rao⁹ | Patricio Chrem Mendez¹⁰ | Sandra E. Black¹¹ | Kuncheng Li¹² | Takeshi Iwatsubo¹³ | Chiung-Chih Chang¹⁴ | Ana Luisa Sosa¹⁵ | Christopher C. Rowe¹⁶ | Richard J. Perrin¹⁷ | John C. Morris¹⁸ | Amanda M.B. Healan¹⁹ | Stephen E. Hall¹ | Michael W. Weiner²⁰

¹ Alzheimer's Association, Chicago, Illinois, USA

² School of Public Health and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA

³ Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA

⁴ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

⁵ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Institute on Aging, Perelman School of Medicine, Alzheimer's Disease Core Center, Perelman School of Medicine, Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

⁶ Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA

⁷ Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA

⁸ Merck Research Laboratories, Merck, Kenilworth, New Jersey, USA

⁹ Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India

¹⁰ Centro de Memoria, FLENIMontañeses, 2325 (C1428AQK), Bs As, Buenos Aires, Argentina

¹¹ Department of Medicine (Neurology), Hurvitz Brain Sciences Program, Canadian Partnership for Stroke Recovery, and LC Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

¹² Department of Radiology, Xuanwu Hospital of Capital Medical University, Beijing, China

¹³ Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

¹⁴ Department of General Neurology and Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

¹⁵ National Institute of Neurology and Neurosurgery of Mexico, Mexico City, Mexico

¹⁶ Department of Molecular Imaging and Therapy, Austin Health and Florey Department of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia

¹⁷ Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of Pathology and Immunology, Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA

¹⁸ Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA

¹⁹ Independent Science Writer and Editor, Nashville, Tennessee, USA

²⁰ Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, Department of Radiology, Department of Medicine, Department of Psychiatry, Department of Neurology, University of California, San Francisco, California, USA

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals, LLC on behalf of Alzheimer's Association

Correspondence

Christopher J Weber, Director, Global Science Initiatives, Alzheimer's Association, 225 N. Michigan Ave. 18th floor, Chicago, IL 60601, USA.
Email: cweber@alz.org

Abstract

The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

KEYWORDS

Alzheimer's disease, amyloid, biomarkers, cerebrospinal fluid, cognitive impairment, MRI, neuroimaging, PET, Tau

1 | INTRODUCTION

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, naturalistic study to understand structural, biochemical, and cognitive changes that occur during Alzheimer's disease (AD) progression. ADNI investigators leverage imaging, blood, and cerebrospinal fluid (CSF) analysis, and clinical, genetic, and postmortem neuropathologic databases to define markers for each stage of AD.¹ Data obtained through ADNI are used to inform clinical trial design and sufficiently power trials. ADNI data can also help establish outcome measures and identify appropriate trial participants.

North American ADNI investigators are organized into distinct cores centered around: positron emission tomography (PET), magnetic resonance imaging (MRI), fluid (blood, CSF) biomarkers, genetics, biostatistics, autopsy neuropathology, and clinical data with an informatics core for widespread data sharing without embargo. More broadly, Worldwide ADNI (WW-ADNI) now encompasses neuroimaging initiatives from nine distinct regions. It serves as the umbrella organization for North American ADNI, Argentina ADNI, Australia ADNI (AIBL), Canada ADNI, China ADNI, Japan ADNI, Korea ADNI, Mexico ADNI, and Taiwan ADNI. Biologic samples are shared and all WW-ADNI investigators are tasked with harmonizing research methodologies so that data can be readily combined.

1.1 | WW-ADNI evolution

WW-ADNI is the result of several successive phases. The first phase, ADNI-1, launched in 2004. ADNI-1 established much of the organizational structure still in place within the North American ADNI,

including core facilities.^{2,3,4} In total, 821 participants with and without mild cognitive impairment (MCI) or AD enrolled in ADNI-1 across 57 study sites.¹

Two subsequent phases followed: ADNI "Grand Opportunities" (ADNI-GO) and ADNI-2. ADNI-GO supported amyloid PET scans for ADNI-1 participants plus enrollment of 200 early MCI participants.⁵ ADNI-2 further expanded the study population by 550 to include people with other forms of memory impairment.

A 5-year competitive renewal of ADNI-2, called ADNI-3, began in 2016. ADNI-3 is actively enrolling up to 1200 additional participants across the entire spectrum of AD. ADNI-3 has moved research and study enrollment tools to the web to improve accessibility (<http://adni.loni.usc.edu/>) and introduced longitudinal tau PET scans. A major goal of ADNI-3 is to validate longitudinal tau PET imaging. Considerably more than 2000 participants have been enrolled since 2004.

Although ADNI-3 currently includes 59 study sites in North America, international collaboration continues through WW-ADNI, with support from the Private Partner Scientific Board (PPSB).⁶ WW-ADNI's expansive, global network has produced more than 3500 publications.^{1,5,7} This body of work provides a foundation for the next phase, ADNI-4, a competitive application for renewal of ADNI-3 slated for September 2021. In August 2020, WW-ADNI investigators held a virtual meeting to share updates and their vision for ADNI-4.

2 | NORTH AMERICAN ADNI

Since 2004, North American ADNI investigators have enrolled more than 2000 study participants (at least 955 MCI, 350 AD, and 505 cognitively unimpaired) across 59 study sites.

2.1 | PET core

The PET core has amassed thousands of brain PET scans that can be downloaded by qualified users. The scans employ ^{18}F -labeled tracers: florbetapir (Amyvid), florbetaben (Neuraceq), flortaucipir (Tauvid), and fluorodeoxyglucose. The core has established methods to control variability in PET scan data.⁸ Longitudinal data are now available for florbetapir and flortaucipir PET scans. For example, WW-ADNI's collection of florbetapir images, which began with ADNI-1, now includes baseline, 1307; second, 769; third, 453; fourth, 246; fifth, 84; and sixth, 5 sequential florbetapir PET scans.

The core has established interrelationships between PET markers. Amyloid appears to drive cortical tau accumulation and is a more significant marker of tau burden than MCI diagnosis.⁹ By characterizing individuals according to the current research framework,¹⁰ individuals in ADNI were classified according to ATN (amyloid, tau, neurodegeneration) criteria. Those who were positive for all three biomarkers showed the greatest cognitive impairment. In longitudinal data, brain amyloid beta ($A\beta$) drives tau accumulation, and tau accumulation drives neurodegeneration. The presence of high tau and neurodegeneration is linked to cognitive decline. There is no evidence that tau levels lead to greater β -amyloid deposition, or that neurodegeneration leads to tau deposition. Together these results are consistent with a unidirectional pathway linking amyloid, tau, and neurodegeneration in a sequential pattern leading to cognitive decline and dementia.¹¹

2.2 | MRI core

The MRI core uses several sequences, including three-dimensional (3D) T1 volume, 3D fluid-attenuated inversion recovery (FLAIR), and T2* gradient echo (GRE), plus associated measurements. The core's technical capacities also include diffusion-weighted MRI (dMRI), arterial spin labeling (ASL) in 2D and 3D, task-free functional MRI (TF-fMRI), and coronal high-resolution T2 sequences.^{5,12} The core has developed standardized protocols⁵ for these sequences that can be employed across WW-ADNI.

The core has developed basic and advanced protocols⁹ to accommodate MRI system variability and evolving operating systems. ADNI-3 imaging is being performed exclusively on 3T scanners. The core is performing meta-analyses of site-specific effects,¹³ random-effects regressions to identify scanner-specific effects, and adjusting data before pooling¹⁴ or encoding it to eliminate bias.¹⁵

A newly identified risk has been the potential identification of participants based on MRI, through publicly available facial recognition software.¹⁶ Standard MRI de-identification removes only metadata (text). Removing or blurring face voxels can compromise other measurements, particularly in the frontal regions.¹⁷ A committee within the MRI core is now charged with determining which defacing algorithms are most effective at anonymization while preserving data integrity.

RESEARCH IN CONTEXT

1. Systematic review: The WW-ADNI meeting provided investigators an opportunity to share updates from ADNI-3 and a look forward to the development of ADNI-4.
2. Interpretation: WW-ADNI is a global, collaborative effort to investigate imaging and biofluid markers that can inform AD treatment trials.
3. Future directions: ADNI-4 looks to build on the success of previous phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3) through validation of emerging biomarkers, and a focus on their generalizability and their relationships to cognitive decline and dementia symptoms.

2.3 | Biomarker core

With ADNI-3, the Biomarker core's collection of CSF, plasma, and serum grew by > 1700 samples for new enrollees and > 1600 for rollover participants. More than half (55%) of all new participants have received a lumbar puncture. The core has standardized biofluid collection and processing^{18,19} across WW-ADNI sites. The core has also standardized ultraperformance liquid chromatography-tandem mass spectrometry (MS)^{3,20} and multiplexed MS.²¹ In ADNI-3, the core revised their protocol to reduce total collection time for plasma samples to under 1 hour.

The core has worked with the Foundation for the National Institutes of Health - Biomarkers Consortium (FNIH - BC) to conduct a multi-center study using replicate sets of 130 ADNI plasma aliquot samples distributed to each of six participating centers. Results and analyses will be conducted in early 2021. The core has shipped >30,000 aliquots to researchers around the world who provided data for additional pathologic pathways (eg, neurogranin, Neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), Neuronal Pentraxin 2 (NPTX2)) following review and approval by the WW-ADNI Resource Allocation Review Committee (RARC).²¹⁻²⁴ RARC is made up of non-ADNI investigators and serves as a gatekeeper for this precious resource.

In anticipation of increased plasma sample requests in ADNI-4, the core is investigating how factors such as delayed centrifugation, aliquot size, and multiple freeze-thaw cycles affect AD biomarker integrity. Concentration values for the core CSF biomarkers have been determined on >3000 CSF samples collected in the ADNI-1/-GO/-2 and -3 Phases using the highly standardized automated Roche Elecsys system.

2.4 | Genetics core

Although many studies that use Genetics core data focus on APOE and other risk variants,²⁵ ADNI-3 has brought collaborations to study

polygenic risk scores, epigenetics, transcriptomics, proteomics, and metabolomics.

For example, one group integrated data from six multicenter cohort studies (4314 participants). The group successfully identified common variants in *RBFOX1* associated with early brain amyloidosis.²⁶ Another identified genetic determinants of hippocampal volume in 33,536 individuals.²⁷ For Ribonucleic acid (RNA), genomewide transcriptome analyses of ADNI core data identified novel genes dysregulated in AD pathology: *CREB5*, *CD46*, *TMBIM6*, *IRAK3*, and *RPAIN*.²⁸ An epigenome-wide association study identified differentially methylated profiles in peripheral blood between MCI and AD participants.²⁹ Metabolomics researchers within the Genetics core found sex-specific effects. *APOE* ϵ 4-positive women experience greater mitochondria impairment than men do.³⁰ In ADNI-4, the group plans to extend polygenic analyses. The core is also testing deep learning as an approach to analyzing multilayer -omics data.

2.5 | Biostatistics core

This year, due to disruptions caused by the coronavirus disease 2019 (COVID-19) pandemic, the Biostatistics core has been investigating the impact of missing data on longitudinal modeling and analyses. This includes determining whether data collected at home are comparable to clinic data. Participants in CogState studies,¹⁴ for example, complete cognitive tests both at home and in a clinic, with significantly faster response times at home. The core is developing approaches to accommodate this factor when analyzing future cognitive testing data, including in ADNI-4.

The core is also investigating the effects of attrition or scheduling abnormalities caused by COVID-19. The core is determining how adjusting data collection timing (an early or late timestamp) impacts planned analyses and power. Biostatistics core simulations show that a generalized additive mixed-models approach has more power than a mixed model for repeated measures to detect differences when there is a study hiatus, especially if the gap in data collection is long.³¹ In anticipation of ADNI-4, the core is also developing models that allow for time as a continuous (rather than categorical, or timestamped) measurement. This will support adaptations that preserve power even if there are measurement gaps due to COVID-19 or unforeseen circumstances.

2.6 | Neuropathology core

In its original funding period, ADNI-1 did not have provisions for the neuropathologic assessment of deceased ADNI participants or for the establishment of a brain tissue resource; hence, ADNI began without a Neuropathology Core (NPC).

The ADNI NPC was established in 2007 as a “sub-study” of ADNI-1, with an administrative supplement from the National Institute on Aging (NIA), but with very limited resources and no authorization to maintain contact with willing, consented brain donors beyond their

period of active enrollment. As a result, participant tracking was left to individual sites without financial support from ADNI. Although 33 of the 59 North American ADNI sites are associated with established Alzheimer's Disease Research Centers (ADRCs), many of the non-ADRC sites lack independent brain donation programs and/or the capacity to secure brain donations. Consequently, ADNI's brain donation program started slowly, with only 32 sites contributing case material to the NPC by 2020.

In 2021, the ADNI NPC conducted a retrospective review of completed neuropathologic assessments (N = 81). All of these cases were evaluated according to a comprehensive, uniform protocol for $A\beta$ deposits, tauopathy, alpha-synucleinopathy (Lewy body disease), TDP-43 proteinopathy, vascular disease, infarctions, and hemorrhages. Clinicopathologic correlation of those cases revealed that, among ADNI participants with a clinical diagnosis of AD dementia at expiration, 18% did not have sufficient AD neuropathology to account for dementia—in other words, their dementia was not caused by AD. In addition, 85% of the participants whose dementia likely was caused by AD pathology also exhibited features of at least one other neurodegenerative disease with the potential to have contributed to their illness. These findings underscore how essential that neuropathologic confirmation will be for ADNI to develop truly accurate biomarkers for AD and related dementias.

Recognizing the vital importance of neuropathologic confirmation and the potential value of a large brain tissue resource for the discovery and validation of molecular biomarkers of AD and other neurodegenerative pathologies, ADNI Leadership helped the NPC to secure two administrative supplements from the NIA in 2019 and 2020. The first strengthened the central infrastructure and staffing of the ADNI NPC; the second is working to bolster the brain donation program across the entire North American ADNI network.

Over the past 2 years, these investments have allowed the ADNI NPC to expand its resource to >115 brain donations, to identify at least 50 additional ADNI-participant brain donations previously assessed at participating ADRCs, to increase support of ADNI brain donation efforts at participating sites, and to persuade several ADNI sites to join ADNI's brain donation program network for the first time.


As ADNI-4 approaches, the ADNI-NPC will continue its efforts to strengthen and build new connections within the ADNI brain donation network, to expand the tissue resource, and to comprehensively assess all donated specimens for relevant neuropathology. In ADNI-4, the NPC will additionally actively promote, coordinate, and participate in the study of this resource, governed by the ADNI Neuropathology Resource Allocation Review Committee (RARC), to support the scientific initiatives and aims of ADNI and approved extramural investigations.

2.7 | Clinical core

Many ADNI participants have transitioned between diagnostic groups as their disease has progressed. The Clinical core has identified participants who have transitioned from cognitively unimpaired to MCI

TABLE 1 ADNI-3 participants

Overall		CN (N = 509)	MCI (N = 288)	AD (N = 109)	Unknown (N = 63)	Combined (N = 969)
Rollover	969	213 (42%)	126 (44%)	50 (46%)	51 (81%)	440 (45%)
Age	969	73.7 (7.6)	75.2 (8.0)	77.6 (8.8)	78.3 (8.8)	74.9 (8.1)
APOE e4+	762	142 (32%)	76 (39%)	40 (59%)	18 (35%)	276 (36%)
Sex : F	969	300 (59%)	119 (41%)	48 (44%)	31 (49%)	498 (51%)
Education	969	16.8 (2.3)	16.2 (2.6)	15.7 (2.5)	16.3 (2.6)	16.5 (2.5)
Amyloid+	785	141 (31%)	111 (47%)	73 (85%)	1 (33%)	326 (42%)
Minority	969	82 (16%)	37 (13%)	11 (10%)	9 (14%)	139 (14%)
Mini Mental State Examination (MMSE)	922	29.1 (1.2)	27.8 (2.1)	21.8 (4.7)	28.3 (2.6)	27.8 (3.1)
Financial Capacity Instrument (FCI)	839	68.1 (6.0)	60.4 (12.1)	39.7 (18.9)	64.7 (8.1)	63.0 (12.9)
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)	944	0.073 (0.257)	1.484 (1.218)	5.743 (3.290)	3.409 (5.683)	1.309 (2.550)
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog13)	908	12.7 (4.3)	19.3 (6.5)	34.4 (8.5)	15.0 (8.8)	17.3 (8.9)

**FIGURE 1** ADNI-1 through ADNI-4 timeline

and from MCI to AD. These subpopulations are invaluable for modeling studies designed to predict cognitive impairment. Similarly, the core has identified participants who do not progress from early to late MCI or AD, due to genetic or other factors. Table 1 details participant demographics, biomarkers, and assessment results from ADNI-3.

The Clinical core has identified demographic gaps in the ADNI-3 cohort. Currently only 14% of ADNI-3 participants identify as racial or ethnic minorities. Most identify as Caucasian and >90% have a 4-year college education. This spurred formation of a Diversity Taskforce within WW-ADNI. ADNI-4 will employ targeted recruitment strategies, supported by dedicated funding for Black and Latinx participants and recruiters. These efforts will also focus on AD enrollment. Competition with treatment trials significantly impacted AD participant enrollment in ADNI-3.

2.8 | Planning for ADNI-4

Funding for US ADNI-3 ends August 2022, and ADNI-4 planning is underway (Figure 1). A renewal grant for ADNI-4 was submitted to the NIA in Oct 2021. ADNI posted a Request for Proposals on the ADNI website, and received more than 30 responses for plasma, PET, and digital biomarkers. ADNI-4 will be similar to ADNI-3, with several major additions: First, to make ADNI more generalizable, the exclusion criteria will be relaxed. In addition, an Engagement Core will focus on recruiting many more people from the Black, Latino, and Asian commu-

nities, and people with lower socioeconomic status. Second, because of the excitement concerning use of plasma AD markers, ADNI-4 plans to obtain blood from 4000 participants and use the results to select 500 for referral to the ADNI clinics for in-person evaluation, MRI, PET scans, blood tests, genetics, and lumbar puncture. Finally, ADNI is exploring greater use of digital biomarkers.

3 | WORLDWIDE ADNI

WW-ADNI provides a larger platform for ADNI researchers to collaborate. This aligns with a major goal of ADNI throughout its evolution: to standardize protocols and analyses, and to facilitate open access to comparable, worldwide data.³

3.1 | Argentina ADNI

A Buenos Aires team has carried out the ADNI-2 protocol³ in 56 participants under its own financial support. The team has ended ADNI follow-up visits and is now focused on data analysis. Several findings have been described.^{3,32} Participant retention was strong for the 12- and 30-month study visits (50 and 43 participants completed each, respectively). Of the initial cohort, 26 participants completed the final 60-month follow-up MRI and neuropsychiatric assessments (4 participants passed away).

Argentina ADNI researchers investigated biomarker profiles for all participants.^{33,34} At baseline, 85% of the participants in the AD group were positive on amyloid PET scans, for CSF p-tau, and for neurodegeneration. Whereas in the MCI group, this dropped to 50% for suspected non-Alzheimer's pathophysiology participants who were only positive for neurodegeneration at baseline. After 5 years of follow-up, the overall conversion rate to dementia was 21%. Cognitive testing data significantly correlated with CSF amyloid levels in participants³⁵; however, total CSF tau and p-tau were the strongest conversion predictors.^{34,36} The researchers have described the capacity of several biomarkers to predict cognitive impairment.^{37,38} Notably, Argentina ADNI is the first group in Latin America to perform tau PET scans (23 performed to date).

3.2 | Canada ADNI

Canada ADNI is conducting a multisite amyloid and (18)F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) imaging study in 80 AD and vascular patients with severe periventricular white matter disease. Eighty ADNI-2 participants with minimal periventricular white matter hyperintensity (WMH) provide a comparator group. The study aims to understand the additive or interactive effects of small vessel disease and AD.

At baseline and 24 months, study participants completed 3T MRI, 18F-florbetapir, and 18F-FDG-PET scans, blood draws, and gait and cognitive testing. Preliminary analyses compare 57 participants with moderate to severe pvWMH to 57 ADNI-2 MCI or AD participants with minimal pvWMH. Overall, higher pvWMH was associated with elevated brain amyloid burden by PET scan. Participants with minimal pvWMH had lower brain glucose levels.³⁹ Random forest machine-learning algorithms pinpointed several brain regions associated with cognitive ability, most strikingly, the posterior cingulate gyrus. Lower amyloid burden and increased glucose in this region was associated with higher cognitive test scores.⁴⁰ Methods developed by Canada ADNI suggest that simple machine learning can help classify regions of interest in PET scans.

3.3 | China ADNI

China ADNI includes several cores: Clinical, MRI, PET, Pathological, Biomarker and Genetics, Biostatistics and Informatics, and Neuropsychological. China ADNI also has a dedicated Data Storage and Processing site. Since joining WW-ADNI in 2012, China ADNI has investigated the role of traditional Chinese medicine in AD progression.

Foundational fMRI work by China ADNI confirmed that acupuncture at two dorsal Siguan points (Tai chong on the right foot, and Hegu on the right hand)⁴¹ activates brain regions associated with cognition in people with MCI or AD.⁴² Neuroimaging shows that acupuncture at these locations improves blood perfusion, default mode network activity,⁴³ and hippocampal connectivity^{44,45} in AD. A randomized, controlled trial by China ADNI found that 6 months of consistent

acupuncture treatment delayed MCI disease progression. This study compared fMRI from 50 cognitively unimpaired participants to 28 with amnesic MCI.⁴⁶

China ADNI is now launching a larger, randomized controlled trial to further study Siguan acupoints and MCI progression. The study includes measurements of amyloid and tau in blood and/or CSF, a cognitive testing battery, as well as MRI and 18F-FDG-PET in accordance with ADNI protocols. China ADNI intends to enroll 400 amnesic MCI participants across 20 hospitals. Half of participants will receive the acupuncture intervention.

3.4 | Japan ADNI

Japan ADNI launched in 2007³ and has enrolled 537 of a targeted 600 participants in a longitudinal, observational study akin to ADNI-1. Participants at 38 study sites have completed blood and APOE genotyping and 37% have provided a CSF sample. For neuroimaging, 37% and 63% of participants have completed 11C-PiB and 18F-FDG PET imaging, respectively. Japan ADNI data harmonize with North American ADNI study sites.⁴⁷ Combined analyses revealed the APOE $\epsilon 4$ -positive and -negative participants with late MCI or mild AD experienced cognitive decline at the same speed.⁴⁸ Japan ADNI-2, a small preclinical AD study, completed in March 2020, enrolled 28 cognitively unimpaired and 12 MCI participants. The study includes tau PET subanalyses; 15 flortaucipir scans have been completed to date.

Data collected by Japan ADNI have been released for worldwide research use (<https://humandbs.biosciencedbc.jp/en/data-use>). These includes 2715 MRI and 1981 PET images, all biofluid data, as well as case report forms and cognitive testing results for cognitively unimpaired, MCI, and AD participants.

To aid recruitment, research volunteers for preclinical AD studies participate in a web-based study (J-TRC webstudy) to provide basic demographics, clinical histories, and complete cognitive tests. Nearly 4500 have registered. Eligible participants are then invited to a clinic to provide blood samples, undergo florbetapir or flutemetamol amyloid PET, and complete cognitive tests including PACC (J-TRC onsite study). As a last step, risk assessment algorithms select participants most appropriate for treatment trials. This process creates a rich data set even before study enrollment.⁴⁹

3.5 | Taiwan ADNI

Taiwan ADNI has five cores: Clinical, PET, MRI, Biomarkers and Genetics, and Biostatistics and Informatics. The first stage of Taiwan ADNI was similar to ADNI-1 and completed in 2019. Six hospitals participated. Nine sites have joined stage 2 of Taiwan ADNI, which is already underway and adds a Tau Imaging core to the framework. The second stage aims to establish a longitudinal AD cohort. Beyond neuroimaging and biofluid assessments, stage 2 adds behavior, depression, diet, and sleep assessments. Neuroimaging will be assessed, in part, using deep learning algorithms. Stage 2 also includes extensive measures of early

onset dementia genes. To date, Taiwan ADNI has enrolled 137 participants in stage 2.

Taiwan ADNI infrastructure has enabled researchers to assess changes in amyloid deposition due to carotid artery stenosis⁵⁰ and traumatic brain injury.⁵¹ It has also supported PET imaging to better understand how D678H, a familial autosomal mutation common in Taiwan, may increase AD risk.⁵² Similarly, Taiwan ADNI researchers have investigated how late-life depression increases amyloid burden and MCI risk in a Taiwanese population.⁵³

Taiwan ADNI has employed a pre-screening tool for use prior to selecting participants for PET scans. The tool, a simple decision tree coupled with APOE genotyping and amyloid plasma measurements, successfully predicts amyloid PET findings in MCI participants.⁵⁴ This tool could be used by other sites and in clinical trials to avoid unnecessary PET scans.

3.6 | Mexico ADNI

Mexico ADNI is based in the National Institute of Neurology and Neurosurgery of Mexico. With >90,000 consultations at this site annually, there is a strong clinical demand for neuroimaging studies. The group has forged international collaborations and independently implemented ADNI-3-compatible protocols for 3T MRI scans. In parallel, they are completing an analysis of MRI data from 70 original studies.

Several collaborations connect Mexico ADNI to the broader AD research community. Mexico ADNI is enrolling 270 participants across several consortium studies: LatAm Fingers, Dominantly Inherited Alzheimer Network (DIAN), DIAN-trials unit, and ReDLat. All of these studies are supported by the Alzheimer's Association and follow North American ADNI protocols.

3.7 | Australia ADNI

The Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) has been the major focus of Australia ADNI for the past 14 years. The study has enrolled 2691 participants stratified by PET Centiloid level, a technique standardized by Australian and North American ADNI researchers to quantify amyloid burden.⁵⁵ This imaging biomarker identifies participants at highest risk for AD. For example, cognitively normal AIBL participants with >100 Centiloid level at baseline experienced a 50% conversion rate to prodromal AD within 5 years.⁵⁶ The first 6 years of AIBL data are available through the North American ADNI centralized database.

Preliminary analyses of AIBL tau PET MK6240 scans are underway and suggest a 0.5% per year tau increase in cognitively normal amyloid PET-positive participants, but a 2% to 7% annual increase in AD.⁵⁶ Through international collaboration, AIBL is investigating binding of an F-18-labeled tracer to MAO-B, to assess reactive astrocytosis during the development of AD.⁵⁷ Australia ADNI has collaborated with industry partners to ramp up production of tau MK6240 and amy-

loid NAV4694 tracers at five production sites to accommodate growing research needs.

4 | SUMMARY

WW-ADNI has made major strides in amyloid and tau phenotyping, standardizing methodologies, and providing a rich data set for AD researchers around the globe. The group's efforts serve as a foundation for AD treatment trials. WW-ADNI findings can inform participant selection criteria and deeply enhance outcome measures.

As WW-ADNI continues, a major goal will be to validate biomarkers identified to date, with focus on their generalizability and relationships to cognitive decline and dementia symptoms. A goal shared by all WW-ADNI researchers is to enroll more racial and ethnic minorities. To accomplish this, ADNI-4 may relax exclusion criteria related to comorbidities across cognitively unimpaired, MCI, and AD cohorts. This may include allowing participants previously exposed to disease-modifying treatments. Specific inclusion criteria changes will be made in collaboration with the PPSB. ADNI-4 will also allow release of amyloid PET results to participants. This modification is based upon feedback from current study participants and is expected to further support recruitment efforts. ADNI-4 will include a plasma-based screening effort that selects eligible participants for imaging and CSF collection. ADNI-4 is also expected to scale up autopsy neuropathology data collection. If funded, ADNI-4 is expected to begin in August 2022.

ACKNOWLEDGMENTS

Elecsys is a registered trademark of Roche.

FUNDING INFORMATION

CCC's WW-ADNI project is sponsored by Chang Gung Memorial Hospital, CMRPG 8J0522. AJS receives support from multiple NIH grants related to analysis of ADNI data (P30 AG010133, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, and U01 AG068057). The National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) provides support for ADNI Genetics Core Biobanking and is supported by the NIH (U24 AG021886). CCR has received funding from the National Health and Medical Research Council of Australia. SEB has received funding from the Canadian Institutes of Health Research Foundation Grant (#159910, #142381, and #112246) and the LC Campbell Foundation. LMS has Grant support for AD biomarker studies in CSF and plasma: ADNI3 grant, Biomarker Core, U19AG024904; UPenn ADRC P30AG010124; and MJFox Foundation for Parkinson's Research, grant #005441.

CONFLICTS OF INTEREST

WJ has served as a consultant to Bioclinica, Biogen, CuraSen, Grifols, and Roche/Genentech. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR

Foundation, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. AJS and the Indiana University ADRC receives in-kind PET precursor support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly. CS is a full-time employee of Merck and Co., Inc. and owns shares in the company. CCR has received institutional research grants from Cerveau Technologies, Biogen, Eisai, Abbvie, Roche, and Janssen, and is also participating in Scientific Advisory Boards for Cerveau Technologies and Biogen Australia. LMS is supported by the NIA ADNI-3 grant for which he provides QC oversight for CSF analyses using the Roche Elecsys automated platform and reagents, and has also received IIS grant support for AD biomarker studies from Roche.

REFERENCES

- Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC. The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. *Alzheimers Dement*. 2013;9(5):e111–e194. <https://doi.org/10.1016/j.jalz.2013.05.1769>
- Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. *Neuroimaging Clin N Am*. 2005;15:869–877. <https://doi.org/10.1016/j.nic.2005.09.008>
- Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative. *Cognition Dement*. 2006;5:56–62. <https://doi.org/10.1016/j.jalz.2005.06.003>
- Weiner MW, Aisen PS, Jack CR, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. *Alzheimers Dement*. 2010;6(3):202–211. <https://doi.org/10.1016/j.jalz.2010.03.007>. e7.
- Jack Jr CR, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. *Alzheimers Dement*. 2010;6(3):212–220. <https://doi.org/10.1016/j.jalz.2010.03.004>
- Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J. Perspective: the Alzheimer's disease neuroimaging initiative and the role and contributions of the private partner scientific board (PPSB). *Alzheimers Dement*. 2015;11:840–849. <https://doi.org/10.1016/j.jalz.2015.04.001>
- Veitch DP, Weiner MW, Aisen PS, et al. Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's disease neuroimaging initiative. *Alzheimers Dement*. 2019;15(1):106–152. <https://doi.org/10.1016/j.jalz.2018.08.005>
- Schmidt ME, Chiao P, Klein G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. *Alzheimers Dement*. 2015;11(9):1050–1068. <https://doi.org/10.1016/j.jalz.2014.09.004>
- Tosun D, Landau S, Aisen PS, et al. Association between tau deposition and antecedent amyloid- β accumulation rates in normal and early symptomatic individuals. *Brain*. 2017;140(5):1499–1512. <https://doi.org/10.1093/brain/awx046>
- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535–562. <https://doi.org/10.1016/j.jalz.2018.02.018>
- Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Alzheimer's disease neuroimaging initiative. longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology. *Biol Psychiatry*. 2020. <https://doi.org/10.1016/j.biopsych.2020.06.029>. S0006-3223(20)31739-X. Epub ahead of print.
- Jack Jr CR, Barnes J, Bernstein MA, et al. Magnetic resonance imaging in Alzheimer's neuroimaging initiative 2. *Alzheimers Dement*. 2015;11(7):740–756. <https://doi.org/10.1016/j.jalz.2015.05.002>
- Sten JL, Medland SE, Arias Vasquez A, et al. Identification of common variants associated with human hippocampal and intracranial volumes. *Nat Genet*. 2012;44(5):552–561.
- Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics*. 2007;8(1):118–127. <https://doi.org/10.1093/biostatistics/kxj037>
- Moyer D, Ver Steeg G, Tax Chantal MW, Thompson PM. Scanner invariant representations for diffusion MRI harmonization. *Magn Reson Med*. 2020;84(4):2174–2189. <https://doi.org/10.1002/mrm.28243>
- Schwarz CG, Kremers WK, Therneau TM, et al. Identification of anonymous MRI research participants with face-recognition software. *N Engl J Med*. 2019;381(17):1684–1686.
- Paltoo DN, Lyman Rodriguez L, Feolo M, et al. Data use under the NIH GWAS data sharing policy and future directions. *Nat Genet*. 2014;46(9):934–938. <https://doi.org/10.1038/ng.3062>
- Kang J-H, Korecka M, Figurski MJ, et al. The Alzheimer's disease neuroimaging initiative 2 biomarker core: a review of progress and plans. *Alzheimers Dement*. 2015;11(7):772–791. <https://doi.org/10.1016/j.jalz.2015.05.003>
- O'Bryant S, Gupta V, Henriksen K, et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. *Alzheimers Dement*. 2015;11(5):549–560. <https://doi.org/10.1016/j.jalz.2014.08.099>
- Korecka M, Figurski MJ, Landau SM, et al. Analytical and clinical performance of amyloid-beta peptides measurements in CSF of ADNIGO/2 participants by an LC-MS/MS reference method. *Clin Chem*. 2020 Apr 1;66(4):587–597. <https://doi.org/10.1093/clinchem/hvaa012>
- Spellman DS, Wildsmith KR, Honigberg LA, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's disease neuroimaging initiative (ADNI) CSF. *Proteomics Clin Appl*. 2015;9(7-8):715–731. <https://doi.org/10.1002/prca.201400178>
- Libiger O, Shaw LM, Watson MH, et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. *Alzheimers Dement*. 2021. <https://doi.org/10.1002/alz.12353>
- Ewers M, Biechele G, Suárez-Calvet M, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. *EMBO Mol Med*. 2020;12(9):e12308. <https://doi.org/10.15252/emmm.202012308>. Epub 2020 Aug 10.
- Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. *Brain*. 2015;138(Pt 11):3373–3385. <https://doi.org/10.1093/brain/awv267>. Epub 2015 Sep 15.
- Apostolova LG, Risacher SL, Duran T, et al. Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis. *JAMA Neurol*. 2018;75(3):328–341.
- Raghavan NS, Dumitrescu L, Mormino E, et al. Association between common variants in RBF1, an RNA-binding protein, and brain amyloidosis in early and preclinical Alzheimer disease. *JAMA Neurol*. 2020;77(10):1–11. <https://doi.org/10.1001/jamaneurol.2020.1760>
- Hibar DP, Adams Hieab HH, Jahanshad N, et al. Novel genetic loci associated with hippocampal volume. *Nat Commun*. 2017;8:13624. <https://doi.org/10.1038/ncomms13624>
- Nho K, Nudelman K, Allen M, et al. Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. *Alzheimers Dement*. 2020;16(9):1213–1223. <https://doi.org/10.1002/alz.12092>
- Vasanthakumar A, Davis JW, Idler K, et al. Harnessing peripheral DNA methylation differences in the Alzheimer's disease neuroimaging initiative (ADNI) to reveal novel biomarkers of disease. *Clin Epigenetics*. 2020;12(1):84. <https://doi.org/10.1186/s13148-020-00864-y>

30. Arnold M, Nho K, Kueider-Paisley A, et al. Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum metabolome. *Nat Commun*. 2020;11(1):1148. <https://doi.org/10.1038/s41467-020-14959-w>
31. Donohue MC, Sethuraman G, Langford O, et al. Alternatives to MMRM for preclinical Alzheimer's clinical trials. [Conference presentation]. 2020.JSM 2020 Virtual Conference, online. <https://ww2.amstat.org/meetings/jsm/2020/OnlineProgram/AbstractDetails.cfm?abstractid=312809>
32. Allegri RF, Chrem Méndez P, Calandri I, et al. Prognostic value of ATN Alzheimer's biomarkers: 60-month follow-up results from the Argentine Alzheimer's disease neuroimaging initiative. *Alzheimers Dement (Amst)*. 2020;12(1):e12026. <https://doi.org/10.1002/dad2.12026>
33. Chrem Méndez P, Calandri I, Nahas F, et al. Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up. *Arq Neuropsiquiatr*. 2018;76(4):231–240. <https://doi.org/10.1590/0004-282x20180025>
34. Florencia Clarens M, Crivelli L, Calandri I, et al. Neuropsychological profile of Alzheimer's disease based on amyloid biomarker findings results from a South American cohort. *Appl Neuropsychol Adult*. 2020: 1–6. <https://doi.org/10.1080/23279095.2020.1756816>
35. Harris P, Fernandez Suarez M, Surace EI, Chrem Méndez P, Eugenia Martín M, Florencia Clarens M. Cognitive reserve and $A\beta$ 1-42 in mild cognitive impairment (Argentina-Alzheimer's disease neuroimaging initiative). *Neuropsychiatr Dis Treat*. 2015;11:2599–2604. <https://doi.org/10.2147/NDT.S84292>
36. Allegri RF, Pertierra L, Cohen G, et al. A biological classification for Alzheimer's disease - Amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative. *Int Psychogeriatr*. 2019;31(12):1837–1838. <https://doi.org/10.1017/S1041610219000085>
37. Chrem Méndez P, Gabriela C, Maria Julieta R, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. *Am J Alzheimers Dis Other Dement*. 2015;30(6):599–606. <https://doi.org/10.1177/1533317515576387>
38. Julieta Russo M, Cohen G, Chrem Méndez P, et al. Predicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's disease neuroimaging initiative. *Neuropsychiatr Dis Treat*. 2016;12:2199–2206. <https://doi.org/10.2147/NDT.S107051>
39. Zukotynski K, Gaudet V, Kuo PH, et al. The use of random forests to identify brain regions on amyloid and FDG PET associated with MOCA score. *Clin Nucl Med*. 2020;45(6):427–433. <https://doi.org/10.1097/RLU.0000000000003043>
40. Zukotynski K, Gaudet V, Kua PH, et al. The use of random forests to classify amyloid brain PET. *Clin Nucl Med*. 2019;44(10):784–788. <https://doi.org/10.1097/RLU.0000000000002747>
41. Shan Y, Wang Z, Zhao Z, et al. An fMRI study of neuronal specificity in acupuncture: the multiacupoint siguan and its sham point. *Evid Based Complement Alternat Med*. 2014;2014:103491. <https://doi.org/10.1155/2014/103491>
42. Wang Z, Nie B, Li D, et al. Effect of acupuncture in mild cognitive impairment and Alzheimer's disease: a functional MRI study. *PLoS One*. 2012;7(8):e42730. <https://doi.org/10.1371/journal.pone.0042730>
43. Liang P, Wang Z, Qian T, Li K. Acupuncture stimulation of Taichong (Liv3) and Hegu (LI4) modulates the default mode network activity in Alzheimer's disease. *Am J Alzheimers Dis Other Dement*. 2014;29(8):739–748. <https://doi.org/10.1177/1533317514536600>
44. Wang Z, Liang P, Zhao Z, et al. Acupuncture modulates resting state hippocampal functional connectivity in Alzheimer's disease. *PLoS One*. 2014;9(3):e91160. <https://doi.org/10.1371/journal.pone.0091160>
45. Zheng W, Su Z, Liu X, et al. Modulation of functional activity and connectivity by acupuncture in patients with Alzheimer's disease as measured by resting-state fMRI. *PLoS One*. 2018;13(5):e0196933. <https://doi.org/10.1371/journal.pone.0196933>
46. Li H, Wang Z, Yu H, et al. The long-term effects of acupuncture on hippocampal functional connectivity in amci with hippocampal atrophy: a randomized longitudinal fMRI study. *Neural Plasticity*. 2020;2020:6389368. <https://doi.org/10.1155/2020/6389368>
47. Iwatsubo T, Iwata A, Suzuki K, et al. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: harmonization for international trials. *Alzheimers Dement*. 2018;14(8):1077–1087. <https://doi.org/10.1016/j.jalz.2018.03.009>
48. Suzuki K, Hirakawa A, Ihara R, et al. Effect of apolipoprotein E ϵ 4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. *Alzheimers Dement (N Y)*. 2020;6(1):e12007. <https://doi.org/10.1002/trc2.12007>
49. Sato K, Ihara R, Suzuki K, et al. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: application to the Japanese Trial-Ready Cohort study. *Alzheimers Dement: Translat Res Clin Interven*. 2021;7(1):e12135.
50. Huang K-L, Lin K-J, Ho M-Y, et al. Amyloid deposition after cerebral hypoperfusion: evidenced on [(18F)AV-45 positron emission tomography. *J Neurol Sci*. 2012;319(1-2):124–129. <https://doi.org/10.1016/j.jns.2012.04.014>
51. Yang S-T, Hsiao I-T, Hsieh C-J, et al. Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. *J Neurol Sci*. 2015;349(1-2):99–104. <https://doi.org/10.1016/j.jns.2014.12.032>
52. Huang C-Y, Hsiao I-T, Lin K-J, et al. Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation. *J Neurol Sci*. 2019;398:107–116. <https://doi.org/10.1016/j.jns.2018.12.039>
53. Wu K-Y, Lin K-J, Chen C-H, et al. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: evidence of cerebral amyloidosis and hippocampal atrophy. *Brain Behav*. 2018;8(7):e01016. <https://doi.org/10.1002/brb3.1016>
54. Lin S-Y, Lin K-J, Lin P-C, et al. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease. *Alzheimers Res Ther*. 2019;11(1):111. <https://doi.org/10.1186/s13195-019-0566-0>
55. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimer's Dement*. 2015;11(1):1–15. <https://doi.org/10.1016/j.jalz.2014.07.003>
56. van der Kall LM, Truong T, Burnham SC, et al. Association of β -Amyloid level, clinical progression and longitudinal cognitive change in normal older individuals. *Neurology*. 2020;96(5):e662–e670. <https://doi.org/10.1212/WNL.00000000000011222>
57. Villemagne V, Doré V, Okamura N, et al. To tau or to MAO-B? Most of the ^{18}F -THK5351 signal is blocked by selegiline. *J Nucl Med*. 2018;59(1):1644.

How to cite this article: Weber CJ, Carrillo MC, Jagust W, et al. The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. *Alzheimer's Dement*. 2021;7:e12226. <https://doi.org/10.1002/trc2.12226>